Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B85a32d9d4bdf65404fb8963fef36aef7> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B85a32d9d4bdf65404fb8963fef36aef7 NCIT_P378 "NCI" @default.
- B85a32d9d4bdf65404fb8963fef36aef7 type Axiom @default.
- B85a32d9d4bdf65404fb8963fef36aef7 annotatedProperty IAO_0000115 @default.
- B85a32d9d4bdf65404fb8963fef36aef7 annotatedSource NCIT_C157481 @default.
- B85a32d9d4bdf65404fb8963fef36aef7 annotatedTarget "An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor BPI-16350 selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation." @default.